Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is $2.86. In 2022 the company made an earnings per share (EPS) of $2.17 an increase over its 2021 EPS that were of $1.99.
Year | EPS | Change |
---|---|---|
2023 (TTM) | $2.86 | 31.58% |
2022 | $2.17 | 9.01% |
2021 | $1.99 | 15.08% |
2020 | $1.73 | 14.83% |
2019 | $1.51 | -1.68% |
2018 | $1.53 | 4.96% |
2017 | $1.46 | 31.08% |
2016 | $1.11 | -10.33% |
2015 | $1.24 | 13.91% |
2014 | $1.09 | 4.03% |
2013 | $1.05 | -28.81% |
2012 | $1.47 | 108.9% |
2011 | $0.70 | 25.59% |
2010 | $0.56 | 35.01% |
2009 | $0.42 | -9.17% |
2008 | $0.46 | 61.35% |
2007 | $0.28 | 28.96% |
2006 | $0.22 | 25.63% |
2005 | $0.18 | 4.17% |
2004 | $0.17 | 13.55% |
2003 | $0.15 | 36.87% |
2002 | $0.11 | -6.99% |
2001 | $0.12 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Pfizer PFE | $1.86 | -34.87% | ๐บ๐ธ USA |
Eli Lilly LLY | $5.43 | 90.12% | ๐บ๐ธ USA |
Sanofi SNY | $3.18 | 11.36% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | $3.97 | 39.02% | ๐บ๐ธ USA |